首页> 美国卫生研究院文献>Springer Open Choice >Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week single-arm open-label extension study

【2h】

Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week single-arm open-label extension study

机译：Cariprazine在长期精神分裂症治疗中的安全性和耐受性：一项为期48周的单臂开放标签扩展研究的结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

RationaleCariprazine, a dopamine D3/D2 receptor partial agonist antipsychotic, demonstrated efficacy and tolerability in 6-week, randomized, placebo-controlled schizophrenia trials. Schizophrenia is a chronic disorder that requires continuous treatment; therefore, the long-term safety and tolerability profile of antipsychotic agents is an important factor in guiding clinician decisions.

机译：多巴胺D3 / D2受体部分激动剂抗精神病药RationaleCariprazine在6周的随机安慰剂对照精神分裂症试验中证明了疗效和耐受性。精神分裂症是一种需要持续治疗的慢性疾病。因此，抗精神病药的长期安全性和耐受性是指导临床医生决策的重要因素。

著录项

期刊名称 Springer Open Choice
作者
Suresh Durgam; William M. Greenberg; Dayong Li; Kaifeng Lu; Istvan Laszlovszky; Gyorgy Nemeth; Raffaele Migliore; Stephen Volk;
展开▼
作者单位

展开▼
年(卷),期 -1(234),2
年度 -1
页码 199–209
总页数 11
原文格式 PDF
正文语种
中图分类外科学;
关键词
Atypical antipsychotic Dopamine antagonist Cariprazine Open-label Safety Schizophrenia;

机译：非典型抗精神病药;多巴胺拮抗剂;卡比拉嗪;开放标签;安全性;精神分裂症;

相似文献

外文文献
中文文献
专利

1. Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study [J] . Durgam Suresh, Greenberg William M., Li Dayong, Psychopharmacology . 2017,第2期

机译：在精神分裂症的长期治疗中的安全性和耐受性：48周，单臂，开放标签扩展研究的结果
2. Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study [J] . Andrew J.Cutler, SureshDurgam, YaoWang, CNS spectrums . 2018,第1期

机译：精神分裂症患者甘唑嗪的长期安全性和耐受性评价：1年开放标签研究的结果
3. Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2, open-label, 48-week extension study [J] . Panes Julian, DHaens Geert R., Higgins Peter D. R., Alimentary pharmacology & therapeutics. . 2019,第3期

机译：克罗恩疾病患者口服Tofacitinib的长期安全性和耐受性：结果2，开放标签，48周的扩展研究结果
4. Pharmacokinetics and Tolerability of Sublingual Fentanyl in Healthy Japanese and Caucasian Volunteers: Phase I, Open-Label Single-Dose Study [C] . U. Lorch, F. Farrell, J. Kilborn, International Pain Clinic Congress . 2008

机译：健康日本和白种人志愿者舌下芬太尼的药代动力学和耐受性：I期，开放标签单剂量研究
5. Effectiveness and Tolerability (with focus on metabolic effects) of Atypical Antipsychotics in the Treatment of Schizophrenia: A 48-weeks Noninterventional Naturalistic Comparative Study. [D] . Surti, Bakulesh B. 2013

机译：非典型抗精神病药治疗精神分裂症的有效性和耐受性（重点在于代谢作用）：一项48周的非干预性自然主义比较研究。
6. Erratum to: Safety and Tolerability of Levomilnacipran ER in Major Depressive Disorder: Results from an Open-Label 48-Week Extension Study [O] . Rajnish Mago, Giovanna Forero, William M. Greenberg, -1

机译：勘误至：严重抑郁症中左旋米那普仑ER的安全性和耐受性：一项开放标签48周延伸研究的结果
7. Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study [O] . Suresh Durgam, William M. Greenberg, Dayong Li, 2016

机译：Cariprazine在长期精神分裂症治疗中的安全性和耐受性：一项为期48周的单臂开放标签扩展研究的结果

Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week single-arm open-label extension study

摘要

著录项

相似文献

相关主题

期刊订阅